Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McKinsey Exec On Scaling The Rising Compliance Bar, Supply Chain Resilience

Executive Summary

McKinsey & Company's senior partner Vikas Bhadoria, in this second instalment of a wide-ranging interview with Scrip, talks about 'smart quality', the compliance trajectory of Indian firms and also measures by Korea and China to accelerate biosimilar development and innovation.

You may also be interested in...

As Supply Chain Partners Ramp Up For November DSCSA Deadline, US FDA Gives Them Another Year

Potential distribution hitches could spark shortages of legitimate drugs if the system is not fully ready for package-level tracing requirements, US FDA says in delaying enforcement of the program a decade in the making. Poll shows supply chain partners were making significant progress in preparing for the 27 November deadline.

US FDA Warns Intas To Assess Global Quality Following Plant’s Data Integrity Meltdown

Warning letter details extensive GMP and data integrity remediation expectations for Matoda plant and calls for the privately held generic drug manufacturer to immediately confront its corporate quality issues globally.

New China Foreign Investment Policies Include Biopharma Steps

Amid multinationals' accelerating de-risking and divestment moves in China, the country’s State Council has issued revised policies in the biologics manufacturing and gene therapy area, in a bid to attract foreign investment to the sector. But timely and consistent implementation will be key, an EU trade group says.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts